Fresenius Medical Care provides an alternative, a variety of therapeutic apheresis (treatment through the extracorporeal circuit) that aim to selectively adsorb, from the patients' blood, specific components associated to certain diseases.
|
DALI
|
Therapeutic indications for hypercholesterolaemia (homozygous and heterozygous)
|
|
Immunosorba
|
An indicated treatment for autoimmune diseases, namely Guillian-Barré Syndrome, Haemophilia with inhibitors to factor VIII and IX, Dilated Cardiomyopathy, Myasthenia Gravis and Acute Humoral Rejection (AHR).
|
The DALI therapy consists of an LDL apheresis tecnique through the direct adsorption of lipoproteins (without plasma separation). The therapy ensures a removal rate of LDL Cholesterol of up to 76% and of Lipoprotein Lp(a) up to 70%, resulting in the increase of the LDL/HDL ratio at the end of each treatment.
The system shows excellent biocompatibility and is well tolerated by patients. The system is easy to use, safe and secure. As a general rule, treatments are carried out every two weeks and last for an average of 2 hours.
The IMMUNOSORBA® therapy consists of an immunoadsorption therapy procedure where specific antibodies and circulating immune complexes, associated with autoimmune diseases, are removed from the patient's plasma. The adsorption effect derives from the binding affinity of Protein A to the IgG (subclass 1, 2 and 4), IgA and IgM antibodies.
The duration of the treatments usually ranges between 3 to 5 hours and depends also of the patients' clinical evolution.
For further information please contact us at info@nefrodial.si.
